Link

Content

Seoul, Korea — On the 11th, CMES (CEO Sung-Ho Lee), a leading provider of intelligent robotic solutions; Sison Biomaterials (CEO Hee-Kyung Park), a specialized in vitro diagnostics company; and RevoSketch (CEO Sung-Woon Lee), a bioengineering technology company, announced the signing of a tripartite Memorandum of Understanding (MOU) for the joint development and commercialization of a next-generation AI robotics–based ultra-precision early cancer detection platform.

[Photo] CMES–Sison Biomaterials–RevoSketch MOU Signing Ceremony

This agreement marks the beginning of a full-scale collaboration that integrates each company’s core capabilities:
• AI robotics automation technology
• DNA methylation–based early-stage cancer biomarker discovery technology
• Digital PCR–based ultra-sensitive molecular diagnostics technology
• Biofoundry-grade automation system development expertise

Together, these technologies will enable the development of an early cancer detection platform with dramatically enhanced accuracy, reproducibility, and processing speed.

CMES will develop an end-to-end AI robotic automation workflow encompassing sample handling, dispensing, mixing, reaction preparation, and result acquisition for early cancer screening. By applying high-precision 3D vision–based robot guidance technology, the company aims to minimize errors and inefficiencies inherent in manual, labor-intensive processes. CMES will establish a Biofoundry-type automated molecular diagnostics platform optimized for large-scale analysis and high-throughput testing.

Sison Biomaterials will focus on identifying key DNA methylation biomarkers—critical indicators for early cancer screening. The company will also design highly specific and highly sensitive diagnostic panels and lead clinical validation efforts.

RevoSketch will contribute its digital PCR instruments and cartridges optimized for immuno- and genome-based diagnostics, along with its AI-powered platform for automated reagent and diagnostic panel design and advanced analytical algorithms. The company will also participate in the development of interface modules required to integrate software components during automation.

Through this collaboration, the three companies aim to secure exceptional diagnostic accuracy and high-speed data processing capabilities. They plan to establish a fully standardized and automated integrated platform that sets a new benchmark in the ultra-precision molecular diagnostics market. In addition, they will jointly prepare a global commercialization strategy, including international regulatory pathways, partnerships with medical institutions, clinical implementation, and overseas business development.

Sung-Ho Lee, CEO of CMES, stated,
“AI robotics automation technology is now advancing beyond manufacturing and logistics into the realm of precision medicine. By combining the core strengths of our three companies, we will establish a new global standard for ultra-precision early cancer detection platforms and deliver a highly competitive solution to the worldwide market.”

Hee-Kyung Park, CEO of Sison Biomaterials, commented,
“This partnership will enhance the clinical value of our research on highly specific methylation biomarkers for early-stage cancer. By integrating AI and robotics automation into clinical testing and data analysis, we expect to build a diagnostic system that is both accurate and fully standardized.”

Sung-Woon Lee, CEO of RevoSketch, added,
“We will further advance our digital PCR–based ultra-sensitive molecular diagnostic technology to deliver fast and accurate clinical diagnostics. Through interface development that links reagents, analytical instruments, and robotics, we will build a world-class molecular diagnostics platform.”